Spago Nanomedical has announced positive top line data from a clinical phase IIa study in patients with endometriosis. SPAGOPIX-02 study is evaluating the MRI-enhancing effect of the contrast agent pegfosimer manganese. The data confirms that the primary endpoint was met, without compromising safety.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.314 SEK | -1.88% | +3.97% | -3.98% |
05-20 | Spago Nanomedical Provides an Update on Tumorad-01, Trial Proceeds as Planned | CI |
05-02 | Spago Nanomedical AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-3.98% | 10.45M | |
-40.52% | 8.12B | |
+9.28% | 3.62B | |
-23.85% | 1.92B | |
-20.90% | 1.66B | |
+7.02% | 931M | |
+16.42% | 729M | |
-8.73% | 694M | |
-34.69% | 472M | |
+1.59% | 295M |
- Stock Market
- Equities
- SPAG Stock
- News Spago Nanomedical AB
- Spago Nanomedical Announces Positive Top Line Data from a Clinical Phase IIa Study in Patients with Endometriosis